Ana Francisca Teixeira Gomes

Ms. Ana Francisca Teixeira Gomes

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
WMWendjilla Fortunato de Medeiros
Wendjilla Fortunato de Medeiros
AGAna Francisca Teixeira Gomes
Ana Francisca Teixeira Gomes
AAAna Júlia F. C. Aguiar
Ana Júlia F. C. Aguiar
JQJaluza Luana C. de Queiroz
Jaluza Luana C. de Queiroz
IBIngrid Bezerra
Ingrid Bezerra
AMAna Morais
Ana Morais
In the age of information technology and the additional computational search tools and software available, this systematic review aimed to identify potential therapeutic targets for obesity, evaluated in silico and subsequently validated in vivo. The systematic review was initially guided by the research question “What therapeutic targets have been used in in silico analysis for the treatment of obesity?” and structured based on the acronym PECo (P, problem; E, exposure; Co, context). The systematic review protocol was formulated and registered in PROSPERO (CRD42022353808) in accordance with the Preferred Reporting Items Checklist for Systematic Review and Meta-Analysis Protocols (PRISMA-P), and the PRISMA was followed for the systematic review. The studies were selected according to the eligibility criteria, aligned with PECo, in the following databases: PubMed, ScienceDirect, Scopus, Web of Science, BVS, and EMBASE. The search strategy yielded 1142 articles, from which, based on the evaluation criteria, 12 were included in the systematic review. Only seven these articles allowed the identification of both in silico and in vivo reassessed therapeutic targets. Among these targets, five were exclusively experimental, one was exclusively theoretical, and one of the targets presented an experimental portion and a portion obtained by modeling. The predominant methodology used was molecular docking and the most studied target was Human Pancreatic Lipase (HPL) (n = 4). The lack of methodological details resulted in more than 50% of the papers being categorized with an “unclear risk of bias” across eight out of the eleven evaluated criteria. From the current systematic review, it seems evident that integrating in silico methodologies into studies of potential drug targets for the exploration of new therapeutic agents provides an important tool, given the ongoing challenges in controlling obesity.

Verified
Journal Article
Open access
PDF file
AAAna Júlia Aguiar
Ana Júlia Aguiar
JQJaluza Luana Carvalho de Queiroz
Jaluza Luana Carvalho de Queiroz
PSPedro P. A. Santos
Pedro P. A. Santos
CCChristina S. Camillo
Christina S. Camillo
ASAlexandre Serquiz
Alexandre Serquiz
AMAna Morais
Ana Morais
Several studies have sought new therapies for obesity and liver diseases. This study investigated the effect of the trypsin inhibitor isolated from tamarind seeds (TTI), nanoencapsulated in chitosan and whey protein isolate (ECW), on the liver health status of the Wistar rats fed with a high glycemic index (HGLI) diet. The nanoformulations without TTI (CW) and ECW were obtained by nanoprecipitation technique, physically and chemically characterized, and then administered to the animals. The adult male Wistar rats (n = 20) were allocated to four groups: HGLI diet + water; standard diet + water; HGLI diet + ECW (12.5 mg/kg); and HGLI diet + CW (10.0 mg/kg), 1 mL per gagave, for ten days. They were evaluated using biochemical and hematological parameters, Fibrosis-4 Index for Liver Fibrosis (FIB-4), AST to Platelet Ratio Index (APRI) scores, and liver morphology. Both nanoparticles presented spherical shape, smooth surface, and nanometric size [120.7 nm (ECW) and 136.4 nm (CW)]. In animals, ECW reduced (p < 0.05) blood glucose (17%), glutamic oxalacetic transaminase (39%), and alkaline phosphatase (24%). Besides, ECW reduced (p < 0.05) APRI and FIB-4 scores and presented a better aspect of hepatic morphology. ECW promoted benefits over a liver injury caused by the HGLI diet.

Verified
Journal Article
Open access
PDF file
AGAna Francisca Teixeira Gomes
Ana Francisca Teixeira Gomes
WMWendjilla Fortunato De Medeiros
Wendjilla Fortunato De Medeiros
IMIsaiane Medeiros
Isaiane Medeiros
GPGrasiela Piuvezam
Grasiela Piuvezam
JSJULIANA KELLY DA SILVA-MAIA
JULIANA KELLY DA SILVA-MAIA
AMAna Morais
Ana Morais
The Target-Based Virtual Screening approach is widely employed in drug development, with docking or molecular dynamics techniques commonly utilized for this purpose. This systematic review (SR) aimed to identify in silico therapeutic targets for treating Diabetes mellitus (DM) and answer the question: What therapeutic targets have been used in in silico analyses for the treatment of DM? The SR was developed following the guidelines of the Preferred Reporting Items Checklist for Systematic Review and Meta-Analysis, in accordance with the protocol registered in PROSPERO (CRD42022353808). Studies that met the PECo strategy (Problem, Exposure, Context) were included using the following databases: Medline (PubMed), Web of Science, Scopus, Embase, ScienceDirect, and Virtual Health Library. A total of 20 articles were included, which not only identified therapeutic targets in silico but also conducted in vivo analyses to validate the obtained results. The therapeutic targets most frequently indicated in in silico studies were GLUT4, DPP-IV, and PPARγ. In conclusion, a diversity of targets for the treatment of DM was verified through both in silico and in vivo reassessment. This contributes to the discovery of potential new allies for the treatment of DM.

14 April 2023 in Medicine
Verified
Journal Article
Open access
IMIsaiane Medeiros
Isaiane Medeiros
AAAna Júlia Felipe Camelo Aguiar
Ana Júlia Felipe Camelo Aguiar
WMWendjilla Fortunato de Medeiros
Wendjilla Fortunato de Medeiros
AGAna Francisca Teixeira Gomes
Ana Francisca Teixeira Gomes
ESEmilly Guedes Student Oliveira e Silva
Emilly Guedes Student Oliveira e Silva
AMAna Morais
Ana Morais
Background: In silico studies using dynamic simulation or molecular docking have boosted the screening and identification of molecules and/or targets in studies aimed at treating diseases such as obesity and diabetes mellitus, optimizing the development of new drugs. This study aims to describe a systematic review protocol on peptides and proteins evaluated in silico as potential therapeutic agents for obesity or diabetes mellitus. Methods: This protocol followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols and was registered in the International Prospective Register of Systematic Reviews database (number: CRD42022355540). The databases to be searched will be PubMed, ScienceDirect, Scopus, Web of Science, virtual health library, and EMBASE. It will be included in silico studies that evaluate the simulation by dynamics or molecular docking of proteins or peptides involved in treating obesity or diabetes mellitus. Two independent reviewers will select studies, extract data, and assess methodological quality using the adapted Strengthening the reporting of empirical simulation studies. A narrative synthesis of the included studies will be performed for the systematic reviews. Results: This protocol contemplates the production of 2 systematic reviews to be developed focusing on obesity or diabetes mellitus. Conclusion: The reviews will enable knowledge of peptides and proteins involved in research treating these diseases and will emphasize the importance of in silico studies in this context and for the development of future studies.

24 July 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
IMIsaiane Medeiros
Isaiane Medeiros
AGAna Francisca Teixeira Gomes
Ana Francisca Teixeira Gomes
ESEmilly Guedes Oliveira e Silva
Emilly Guedes Oliveira e Silva
IBIngrid Bezerra
Ingrid Bezerra
JSJULIANA KELLY DA SILVA-MAIA
JULIANA KELLY DA SILVA-MAIA
AMAna Morais
Ana Morais
Bioinformatics has expedited the screening of new efficient therapeutic agents for diseases such as diabetes mellitus (DM). The objective of this systematic review (SR) was to understand naturally occurring proteins and peptides studied in silico and subsequently reevaluated in vivo for treating DM, guided by the question: which peptides or proteins have been studied in silico for the treatment of diabetes mellitus? The RS protocol was registered in the International Prospective Register of Systematic Reviews database. Articles meeting the eligibility criteria were selected from the PubMed, ScienceDirect, Scopus, Web of Science, Virtual Health Library (VHL), and EMBASE databases. Five studies that investigated peptides or proteins analyzed in silico and in vivo were selected. Risk of bias assessment was conducted using the adapted Strengthening the Reporting of Empirical Simulation Studies (STRESS) tool. A diverse range of assessed proteins and/or peptides that had a natural origin were investigated in silico and corresponding in vivo reevaluation demonstrated reductions in glycemia and/or insulin, morphological enhancements in pancreatic β cells, and alterations in the gene expression of markers associated with DM. The in silico studies outlined offer crucial insights into therapeutic strategies for DM, along with promising leads for screening novel therapeutic agents in future trials.

7 October 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAna Francisca Teixeira Gomes
Ana Francisca Teixeira Gomes
LSLisandra Mikaely Barboza da Silva
Lisandra Mikaely Barboza da Silva
RCRaissa Beatriz Silvestre Carneiro
Raissa Beatriz Silvestre Carneiro
RDRaquel Costa Silva Dantas-Komatsu
Raquel Costa Silva Dantas-Komatsu
GMGidyenne Christine Bandeira Silva de Medeiros
Gidyenne Christine Bandeira Silva de Medeiros
ALAndré Ducati Luchessi
André Ducati Luchessi
Acute Myocardial Infarction (AMI) is characterized by the presence of injury caused by an ischemic event, which leads to various complications, including Heart Failure (HF), the most severe functional stage of the heart, reducing both quality of life and life expectancy. Among the factors involved in this process, essential trace elements such as zinc and selenium stand out, as they are related to cardiovascular health and may help mitigate the harmful changes resulting from AMI. The objective of this protocol is to detail the development of two systematic reviews to gather scientific evidence on the relationship between zinc and selenium and the prognosis following AMI. This protocol was developed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guideline and registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the code CRD42024574424. Search strategies will be conducted using a combination of controlled and uncontrolled terms combined with Boolean operators, and the following databases will be used: MEDLINE/PubMed, EMBASE, LILACS, Scopus, Web of Science, Trip database, and World Wide Science. Cohort studies that evaluated zinc and selenium in the prognosis after AMI will be included. Two trained researchers will independently select articles, extract data, and assess the risk of bias and the quality of the evidence. A narrative synthesis will be performed, and the main findings will be presented in tables. If possible, a meta-analysis will also be conducted.